Company: CERO
Filing Date: 2025-08-11
Form Type: S-3
Source: 0001213900-25-073849
Chunk: 20

Company: CERO THERAPEUTICS HOLDINGS, INC.
Filing Date: 2025-08-11
Form: S-3
Chunk 20
---
 These factors could also make it more difficult for us to raise additional funds through future offerings of shares of our
Common Stock or other securities.

<div align='center'>6

USE OF PROCEEDS</div>

All of the shares of Common Stock offered by the
Selling Stockholders pursuant to this prospectus will be sold by the Selling Stockholders for their respective accounts. We will not receive
any of the proceeds from these sales.

The Selling Stockholders will pay any underwriting
fees, discounts, selling commissions, stock transfer taxes and certain legal expenses incurred by such Selling Stockholders in disposing
of their shares of Common Stock, and we will bear all other costs, fees and expenses incurred in effecting the registration of such securities
covered by this prospectus, including, without limitation, all registration and filing fees, Nasdaq listing fees, and fees and expenses
of our counsel and our independent registered public accountants.

<div align='center'>7

SELLING STOCKHOLDERS</div>

The shares of common stock being offered by the
selling stockholders are those issuable to the selling stockholders upon conversion of the Series D Preferred Stock. For additional information
regarding the issuance of the Series D Preferred Stock, see “Fourth PIPE Financing” above. We are registering the shares of
common stock in order to permit the selling stockholders to offer the shares for resale from time to time.

The table below lists the selling stockholders
and other information regarding the beneficial ownership (as determined under Section 13(d) of the Securities Exchange Act of 1934, as
amended, and the rules and regulations thereunder) of the shares of common stock held by each of the selling stockholders. The second
column lists the number of shares of common stock beneficially owned by the selling stockholders, based on their respective ownership
of shares of common stock and Series D Preferred Stock, as of August 1, 2025, assuming conversion of the Series D Preferred Stock held
by each such selling stockholder on that date but taking account of any limitations on conversion and exercise set forth therein.

The third column lists the shares of common stock
being offered by this prospectus by the selling stockholders and does not take in account any limitations on conversion of the Series
D Preferred Stock set forth therein.

In accordance with the terms of a registration
rights agreement with the holders of the Series D Preferred Stock, we are obligated under this prospectus to generally cover the resale
of 250% of